Elizabeth Holmes is one of the few real people who functions as a mythological object. She arrived in Silicon Valley at 19 with a promise to democratize blood testing, cultivated a persona borrowed wholesale from Steve Jobs, raised $945 million, became America's youngest self-made female billionaire at a paper valuation of $9 billion — and built every last bit of it on technology that didn't work. The technology never worked. The blood clotted in the microfluidics. The patents, when Stanford's John Ioannidis examined them, were mostly nonsensical. And yet for over a decade, Henry Kissinger, George Shultz, Rupert Murdoch, Larry Ellison, and Carlos Slim sat on her board or wrote her checks. The new Nathan Fielder and Lance Oppenheim documentary You Can See Everything is the latest — and arguably the most formally ambitious — attempt to answer the question that historian Margaret O'Mara frames plainly: who is the real Elizabeth Holmes? It was filmed across the 34 days before Holmes reported to federal prison camp Bryan in Texas to begin her 11-year sentence for wire fraud and conspiracy. Fielder's camera captures lavalier-miked bedtime stories, naked showers, egg-whisking corrections, and domestic banality. What it cannot capture is the interior. That interiority problem is the engine of the Holmes fascination. David Agus, the medical oncologist who interviewed her at a health conference, describes the encounter as meeting two separate people: one pleasant in the green room, one transformed on stage — accent deepened, gaze unflinching, personality reorganized. It is a performance so total that it looks like dissociation. John Ioannidis offers the most careful reading: not a pure charlatan, he suggests, but someone who believed she could attract capital and talent first, and manufacture the reality second. Silicon Valley ran on this logic. Holmes just applied it to blood tests, where failure costs lives. The film's most striking revelation arrives off-camera. Even as Holmes was preparing to enter prison, she and her partner Billy Evans were actively planning a new medical tech startup. In 2025, two years into her sentence, Evans sought $18.5 million for Haemanthus — a company allegedly holding patents for a device that scans blood, urine, and saliva using lasers. The shape of the story is the same. The technology is unproven. The pitch is familiar. Whether this is pathology or persistence, delusion or audacity, the documentary cannot say, which is either its central failure or its central achievement. The Dropout, the 2022 Hulu miniseries starring Amanda Seyfried, handled the same material as conventional true-crime biography: rise, hubris, fall, reckoning. Fielder is doing something structurally different — using his particular brand of documentary absurdism to hold the camera on Holmes until the performance breaks. It doesn't break. Or rather: you cannot tell whether what you're watching is the performance breaking or just a more intimate version of the same performance. That ambiguity is either brilliant filmmaking or a $9 billion confidence trick replicated at documentary scale. The Guardian's own reviewer called it 'a modern masterpiece of deceit.' The evidence for both readings is in the frame. O'Mara's broader warning is the one that lingers. The cautionary tale of Theranos extends well past Holmes as Silicon Valley pours unprecedented capital into artificial intelligence — a field that runs, structurally, on the same dynamics: charismatic founders, unfalsifiable promises, investors who want to believe, and a press cycle that rewards the story over the data. Holmes did not invent this dynamic. She just pushed it into a domain — medical diagnostics — where the gap between promise and delivery gets people hurt. The next Holmes may be working in a field where that gap is harder to see.
